At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive Cancer Center, Duarte, CA, discusses the results of a randomised, phase 2, three-arm trial of lenvatinib, everolimus, and lenvatinib combined with everolimus in patients with metastatic renal cell carcinoma.
Phase 2 trial of lenvatinib and everolimus for metastatic renal cell carcinoma
26th August 2015
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now